[1] Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. The Lancet, 2015, 385:441-451.
[2] Galasso G, Schiekofer S, D'Anna C, et al. No-Reflow Phenomenon: Pathophysiology, Diagnosis, Prevention, and Treatment. A Review of the Current Literature and Future Perspectives. Angiology, 2014, 65:180-189.
[3] The Lancet: 40 years of percutaneous coronary interven-tion: Where next? Lancet, 2017; 390: 715
[4] Eeckhout E , Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J. 2001, 22:729-739.
[5] Stone GW, Peterson MA, Lansky AJ, Dangas G, Meenran R, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. J Am Coll Cardiol, 2002; 39: 591e597
[6] Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J, 2003; 145: 42-46)
[7] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.)
[8]C. Wang and Q. Jing, “Non-coding RNAs as biomarkers for acute myocardial infarction,” Acta Pharmacologica Sinica, vol. 39, no. 7, pp. 1110–1119, 2018.)
[9] Jakob P, Kacprowski T, Briand-Schumacher S, et al. Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. Eur Heart J. 2017, 38:511.
[10] Emmrich S, Henke K, Hegermann J, Ochs M, Reinhardt D, Klusmann JH. miRNAs can increase the efficiency of ex vivo platelet generation. Ann Hematol 2012; 91:1673–1684.
[11] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138: e618-e651. doi: 10.1161/CIR.0000000000000617.
[12] Borja Ibanez, Stefan James, Stefan Agewall, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119–177. doi: 10.1093/eurheartj/ehx393.
[13] Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.
[14] Gibson CM, Murphy SA, Morrow DA, et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004; 148:336–340
[15] Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55:611-22.
[16] Fung E C, Butt A N, Eastwood J, et al. Circulating microRNA in cardiovascular disease[J]. Advances in clinical chemistry, 2019, 91: 99-122.)
[17]Karimianpour A, Maran A. Advances in coronary no-reflow phenomenon—a contemporary review[J]. Current atherosclerosis reports, 2018, 20(9): 44.)
[18] Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. ProcNatl Acad Sci U S A 2002;99:7634–9.
[19] Chaitman B, Lim B. No reflow and the quest to achieve optimal perfusion during the acute phase of myocardial infarction. J Am Coll Cardiol 2004; 44:313–315.
[20] Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005;46:284–90.
[21] Niccoli G, Celestini A, Calvieri C. Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion. Eur Heart J Acute Cardiovasc Care. 2013;2:379–88.)
[22] Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet reactivity in acute myocardial infarction treated with prymari angioplasty- influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J .2007; 154:62–70
[23] Aurigemma C, Scalone G, Tomai F, et al. Persistent enhanced platelet activation in patients with acute myocardial infarction and coronary microvascular obstruction: clinical implications. Thromb Haemost. 2014; 111:122-30.
[24] Niccoli G, Giubilato S, Russo E, et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J. 2008; 29:1843-50.
[25] Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A.2006; 103:5078–5083
[26] Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res.2009; 37(Database issue): D105–D110.
[27] Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol.2005; 46:284–290.
[28] Martin J, Bath PMW, Burr ML. Increased platelet size following myocardial infarction is associated with subsequent death and nonfatal reinfarction. Lancet. 1991; 338:1409–11